Clinical Outcomes of Haploidentical Transplantation Combined With Umbilical Cord Blood and Mesenchymal Stem Cells Co-Infusion for Aplastic Anemia: A Single-Center Retrospective Study
Transplantation Proceedings · 2026-05 · 58 (4) · 808-815
DOI: 10.1016/j.transproceed.2026.03.017 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transplantation Proceedings, 2026-05. Verfasst von Zhengwei Tan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Traditional Chinese M…. Hauptthemen laut MEDLINE: Anemia, Aplastic, Mesenchymal Stem Cell Transplantation, Cord Blood Stem Cell Transplantation, Transplantation, Haploidentical. Die Arbeit nennt 40 Literaturangaben.
Abstract (Originalsprache)
Haploidentical hematopoietic stem cell transplantation (HID-HSCT) is a critical therapeutic option for severe aplastic anemia (SAA) patients lacking HLA-matched donors. However, its application has been limited by graft failure and graft-versus-host disease (GVHD). The co-infusion of mesenchymal stem cells (MSCs) or umbilical cord blood cells (UCBs) has emerged as a crucial area to enhance transplant outcomes. This single-center retrospective study evaluates the clinical outcomes of HID-HSCT combined with UCBs and MSCs co-infusion in 108 patients. Patients underwent HID-HSCT between January 2018 and January 2025, with 40 receiving co-infusion of UCBs and MSCs. Transplantation outcomes, including neutrophil and platelet engraftment, GVHD incidence, viral reactivation rates, and long-term survival, were compared. Results showed no significant differences in engraftment or GVHD rates between groups. However, the Co-infusion group exhibited a declining trend in grade II-IV aGVHD and significantly improved 5-year overall survival (OS) and graft-versus-host disease-free, relapse-free survival (GRFS). These findings suggest that UCBs and MSCs co-infusion may enhance long-term survival and quality of life in patients undergoing HID-HSCT, offering a promising strategy for clinical haploidentical transplantation. However, the lack of prospective design and standardized protocols limits the conclusions. Future studies should focus on optimizing co-infusion strategies to improve clinical outcomes in haploidentical transplantation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Hematology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Traditional Chinese Medicine), Hangzhou, China; The First School of Clinical Medicine, Zhej…
Zitieren
APA
Tan, Z., Zhao, Y., Hu, H., Yu, Q., Zhang, Y., Wang, B., Hu, T., Wu, D., Ye, B., & Liu, W. (2026). Clinical Outcomes of Haploidentical Transplantation Combined With Umbilical Cord Blood and Mesenchymal Stem Cells Co-Infusion for Aplastic Anemia: A Single-Center Retrospective Study. Transplantation Proceedings, 58(4), 808-815. https://doi.org/10.1016/j.transproceed.2026.03.017
Vancouver
Tan Z, Zhao Y, Hu H, Yu Q, Zhang Y, Wang B, et al. Clinical Outcomes of Haploidentical Transplantation Combined With Umbilical Cord Blood and Mesenchymal Stem Cells Co-Infusion for Aplastic Anemia: A Single-Center Retrospective Study. Transplantation Proceedings. 2026;58(4):808-815. doi:10.1016/j.transproceed.2026.03.017
BibTeX
@article{Tan2026,
author = {Tan, Zhengwei and Zhao, Yuechao and Hu, Huijin and Yu, Qinghong and Zhang, Yu and Wang, Bo and Hu, Tonglin and Wu, Dijiong and Ye, Baodong and Liu, Wenbin},
title = {Clinical Outcomes of Haploidentical Transplantation Combined With Umbilical Cord Blood and Mesenchymal Stem Cells Co-Infusion for Aplastic Anemia: A Single-Center Retrospective Study},
journal = {Transplantation Proceedings},
year = {2026},
volume = {58},
number = {4},
pages = {808--815},
doi = {10.1016/j.transproceed.2026.03.017}
}
EUVIMED